Anpario plc (AIM:ANP)

London flag London · Delayed Price · Currency is GBP · Price in GBX
550.00
+15.00 (2.80%)
May 6, 2026, 3:55 PM GMT
Market Cap109.87M +39.6%
Revenue (ttm)47.18M +23.5%
Net Income6.75M +64.2%
EPS0.38 +55.4%
Shares Out20.54M
PE Ratio14.10
Forward PE12.75
Dividend0.13 (2.34%)
Ex-Dividend DateJul 9, 2026
Volume11,995
Average Volume48,840
Open547.00
Previous Close535.00
Day's Range530.00 - 550.00
52-Week Range370.00 - 580.00
Beta1.02
RSI68.26
Earnings DateJun 10, 2026

About Anpario

Anpario plc, together with its subsidiaries, manufactures and distributes natural animal feed additives for animal health, nutrition, and biosecurity. Its health and performance category offers various products that support and maintain animal gut health, including phytogenic and acid based eubiotics, and omega fatty acids under the Orego-Stim, Optomega, pHorce, Salkil, and Genex brands; and feed quality category provides products, such as enzymes, antioxidants, pellet binders, mould inhibitors, and acid based eubiotics under the pHorce, Feedzy... [Read more]

Founded 1996
Employees 162
Stock Exchange London Stock Exchange AIM
Ticker Symbol ANP
Full Company Profile

Financial Performance

In 2025, Anpario's revenue was 47.18 million, an increase of 23.51% compared to the previous year's 38.20 million. Earnings were 6.75 million, an increase of 64.20%.

Financial Statements

News

Half Year 2025 Anpario PLC Earnings Call Transcript

Half Year 2025 Anpario PLC Earnings Call Transcript

6 months ago - GuruFocus

Full Year 2024 Anpario PLC Earnings Presentation Transcript

Full Year 2024 Anpario PLC Earnings Presentation Transcript

6 months ago - GuruFocus

Anpario Earnings Call Transcript: H1 2025

Revenue rose 34% year-over-year, with strong growth across most regions and a significant contribution from the Bio-Vet acquisition. Gross margin and profitability improved, cash reserves increased, and the outlook remains positive despite ongoing trade and credit risks.

8 months ago - Transcripts

Anpario Earnings Call Transcript: H2 2024

Revenue and profit rebounded strongly with 23% top-line growth and a 57% rise in adjusted EBITDA, driven by broad-based segment recovery and the Bio-Vet acquisition. Gross margins improved, cash remains strong, and the outlook is positive with continued focus on growth and resilience.

1 year ago - Transcripts

Anpario Earnings Call Transcript: H1 2024

Gross margin recovery, strong cash generation, and global diversification underpin optimism for high single-digit sales growth. Ongoing product innovation, M&A, and operational leverage are expected to drive future profit expansion despite regulatory and logistics risks.

1 year ago - Transcripts